As of 2025-07-14, the EV/EBITDA ratio of Avidity Biosciences Inc (RNA) is -8.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Avidity's latest enterprise value is 3,536.78 mil USD. Avidity's TTM EBITDA according to its financial statements is -430.93 mil USD. Dividing these 2 quantities gives us the above Avidity EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.2x - 13.6x | 13.3x |
| Forward P/E multiples | 17.6x - 33.0x | 20.5x |
| Fair Price | (60.67) - (46.51) | (58.31) |
| Upside | -292.9% - -247.9% | -285.4% |
| Date | EV/EBITDA |
| 2025-07-11 | -8.21 |
| 2025-07-10 | -8.21 |
| 2025-07-09 | -8.16 |
| 2025-07-08 | -7.59 |
| 2025-07-07 | -7.47 |
| 2025-07-03 | -7.57 |
| 2025-07-02 | -7.62 |
| 2025-07-01 | -7.37 |
| 2025-06-30 | -7.35 |
| 2025-06-27 | -7.53 |
| 2025-06-26 | -7.75 |
| 2025-06-25 | -7.77 |
| 2025-06-24 | -7.77 |
| 2025-06-23 | -7.56 |
| 2025-06-20 | -7.61 |
| 2025-06-18 | -7.61 |
| 2025-06-17 | -7.62 |
| 2025-06-16 | -7.75 |
| 2025-06-13 | -8.18 |
| 2025-06-12 | -8.40 |
| 2025-06-11 | -8.36 |
| 2025-06-10 | -8.81 |
| 2025-06-09 | -8.55 |
| 2025-06-06 | -9.55 |
| 2025-06-05 | -9.37 |
| 2025-06-04 | -8.98 |
| 2025-06-03 | -9.04 |
| 2025-06-02 | -8.69 |
| 2025-05-30 | -8.08 |
| 2025-05-29 | -8.28 |
| 2025-05-28 | -8.05 |
| 2025-05-27 | -7.90 |
| 2025-05-23 | -7.96 |
| 2025-05-22 | -8.03 |
| 2025-05-21 | -7.98 |
| 2025-05-20 | -8.26 |
| 2025-05-19 | -7.86 |
| 2025-05-16 | -7.90 |
| 2025-05-15 | -7.51 |
| 2025-05-14 | -7.35 |
| 2025-05-13 | -7.77 |
| 2025-05-12 | -7.61 |
| 2025-05-09 | -7.21 |
| 2025-05-08 | -7.44 |
| 2025-05-07 | -6.73 |
| 2025-05-06 | -6.76 |
| 2025-05-05 | -8.44 |
| 2025-05-02 | -8.42 |
| 2025-05-01 | -8.55 |
| 2025-04-30 | -8.54 |